| Title |
Practice Update: Review of Anticonvulsant Therapy
|
|---|---|
| Published in |
Current Neurology and Neuroscience Reports, March 2016
|
| DOI | 10.1007/s11910-016-0640-y |
| Pubmed ID | |
| Authors |
Derek J. Chong, Andrew M. Lerman |
| Abstract |
Since 2010, the Food and Drug Administration has approved the use of four new anti-epilepsy drugs (AEDs) for the treatment of epilepsy in the USA: clobazam (Onfi), ezogabine (Potiga), perampanel (Fycompa), and eslicarbazepine (Aptiom) as well as two extended release formulations, topiramate ER (Qudexy XR and Trokendi) and oxcarbazepine ER (Oxtellar). This not only provides practitioners ample choice to match medication profiles to their patients' preferences and co-morbidities better, but also challenges us to be proficient in the use of all. In addition to providing a brief overview of these new medications and of the current medical management of epilepsy, this review discusses new data regarding vitamin D and AED-related osteoporosis, pregnancy registries, suicidality, marijuana-related compounds for epilepsy, and the recently published guidelines on the approach and management of a first unprovoked seizure in adults and guidelines for when to stop AEDs. |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 145 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 22 | 15% |
| Student > Master | 17 | 12% |
| Other | 16 | 11% |
| Student > Ph. D. Student | 13 | 9% |
| Student > Doctoral Student | 12 | 8% |
| Other | 28 | 19% |
| Unknown | 37 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 11% |
| Neuroscience | 12 | 8% |
| Chemistry | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 6 | 4% |
| Other | 17 | 12% |
| Unknown | 40 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2024.
All research outputs
#4,784,746
of 23,130,383 outputs
Outputs from Current Neurology and Neuroscience Reports
#275
of 921 outputs
Outputs of similar age
#74,241
of 300,826 outputs
Outputs of similar age from Current Neurology and Neuroscience Reports
#10
of 31 outputs
Altmetric has tracked 23,130,383 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 921 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,826 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.